Alzheimer's disease: the amyloid hypothesis and the Inverse Warburg effect

Epidemiological and biochemical studies show that the sporadic forms of Alzheimer's disease (AD) are characterized by the following hallmarks: (a) An exponential increase with age; (b) Selective neuronal vulnerability; (c) Inverse cancer comorbidity. The present article appeals to these hallmarks to evaluate and contrast two competing models of AD: the amyloid hypothesis (a neuron-centric mechanism) and the Inverse Warburg hypothesis (a neuron-astrocytic mechanism). We show that these three hallmarks of AD conflict with the amyloid hypothesis, but are consistent with the Inverse Warburg hypothesis, a bioenergetic model which postulates that AD is the result of a cascade of three events—mitochondrial dysregulation, metabolic reprogramming (the Inverse Warburg effect), and natural selection. We also provide an explanation for the failures of the clinical trials based on amyloid immunization, and we propose a new class of therapeutic strategies consistent with the neuroenergetic selection model.

[1]  M. Beal,et al.  Mitochondria take center stage in aging and neurodegeneration , 2005, Annals of neurology.

[2]  F. Cecconi,et al.  Aβ Toxicity in Alzheimer's Disease , 2012, Molecular Neurobiology.

[3]  J. Deitmer,et al.  Higher transport and metabolism of glucose in astrocytes compared with neurons: a multiphoton study of hippocampal and cerebellar tissue slices. , 2014, Cerebral cortex.

[4]  D. Wheatley The way of the cell , 2001 .

[5]  S. Pimplikar,et al.  Reassessing the amyloid cascade hypothesis of Alzheimer's disease. , 2009, The international journal of biochemistry & cell biology.

[6]  H C Hendrie,et al.  Epidemiology of dementia and Alzheimer's disease. , 1998, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[7]  D. Selkoe,et al.  Preventing Alzheimer’s Disease , 2012, Science.

[8]  Jörg R. P. Geiger,et al.  Energy-Efficient Action Potentials in Hippocampal Mossy Fibers , 2009, Science.

[9]  György Buzsáki,et al.  Predominant Enhancement of Glucose Uptake in Astrocytes versus Neurons during Activation of the Somatosensory Cortex , 2010, The Journal of Neuroscience.

[10]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[11]  Michael A. Rogawski,et al.  Neuroprotective and disease-modifying effects of the ketogenic diet , 2006, Behavioural Pharmacology.

[12]  L. Demetrius,et al.  Directionality principles in thermodynamics and evolution. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  H. Lehrach,et al.  Age-related transcriptional changes in gene expression in different organs of mice support the metabolic stability theory of aging , 2008, Biogerontology.

[14]  D. Wallace The mitochondrial genome in human adaptive radiation and disease: on the road to therapeutics and performance enhancement. , 2005, Gene.

[15]  M. Mattson,et al.  Ageing and neuronal vulnerability , 2006, Nature Reviews Neuroscience.

[16]  Victor S. Van Laar,et al.  The interplay of neuronal mitochondrial dynamics and bioenergetics: Implications for Parkinson's disease , 2013, Neurobiology of Disease.

[17]  S. Laughlin,et al.  An Energy Budget for Signaling in the Grey Matter of the Brain , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  S. Moncada,et al.  The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C–Cdh1 , 2009, Nature Cell Biology.

[19]  D. Mann Alzheimer's disease and Down's syndrome , 1988, Histopathology.

[20]  P. Magistretti,et al.  Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Quinn,et al.  Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. , 2004, Human molecular genetics.

[22]  Alzheimer’s as a metabolic disease , 2013, Biogerontology.

[23]  L. Hayflick Biological Aging Is No Longer an Unsolved Problem , 2007, Annals of the New York Academy of Sciences.

[24]  G. Perry,et al.  Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. , 2006, Journal of Alzheimer's disease : JAD.

[25]  O. Warburg über den Stoffwechsel der Carcinomzelle , 1925, Klinische Wochenschrift.

[26]  Lloyd A. Demetrius,et al.  An inverse-Warburg effect and the origin of Alzheimer’s disease , 2012, Biogerontology.

[27]  M. Beal,et al.  PGC‐1α: overexpression exacerbates β‐amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  Pierre J Magistretti,et al.  Role of the Glyoxalase System in Astrocyte-Mediated Neuroprotection , 2011, The Journal of Neuroscience.

[29]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[30]  J. Blass The Mitochondrial Spiral: An Adequate Cause of Dementia in the Alzheimer's Syndrome , 2000, Annals of the New York Academy of Sciences.

[31]  Yo-El Ju,et al.  Effects of Age and Amyloid Deposition on A␤ Dynamics in the Human Central Nervous System , 2022 .

[32]  Keiko Kobayashi,et al.  Developmental changes in the Ca2+-regulated mitochondrial aspartate-glutamate carrier aralar1 in brain and prominent expression in the spinal cord. , 2003, Brain research. Developmental brain research.

[33]  Albert Gjedde,et al.  Neuronal–Glial Glucose Oxidation and Glutamatergic–GABAergic Function , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  M. Esiri,et al.  Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology , 1999, Acta Neuropathologica.

[35]  R. Brinton,et al.  Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment. , 2011, Current pharmaceutical design.

[36]  J. Tuszynski,et al.  Cancer proliferation and therapy: the Warburg effect and quantum metabolism , 2010, Theoretical Biology and Medical Modelling.

[37]  Leonard Hayflick,et al.  Entropy Explains Aging, Genetic Determinism Explains Longevity, and Undefined Terminology Explains Misunderstanding Both , 2007, PLoS genetics.

[38]  P. Kinnunen CANCER LINKED TO ALZHEIMER DISEASE BUT NOT VASCULAR DEMENTIA , 2010, Neurology.

[39]  D. Wallace,et al.  Mitochondrial energetics and therapeutics. , 2010, Annual review of pathology.

[40]  R. Swerdlow Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging? , 2007, Neurobiology of Aging.

[41]  Fabrizio Chiti,et al.  Amyloid formation by globular proteins under native conditions. , 2009, Nature chemical biology.

[42]  Pierre J Magistretti,et al.  Sweet Sixteen for ANLS , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[43]  P. Reddy,et al.  Mitochondrial Medicine for Aging and Neurodegenerative Diseases , 2008, NeuroMolecular Medicine.

[44]  P. Magistretti,et al.  Activity‐dependent regulation of energy metabolism by astrocytes: An update , 2007, Glia.

[45]  A. Yalçin,et al.  Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. , 2009, Experimental and molecular pathology.

[46]  Lloyd Demetrius,et al.  Boltzmann, Darwin and Directionality theory , 2013 .

[47]  Yuri Zilberter,et al.  Neuronal activity in vitro and the in vivo reality: the role of energy homeostasis. , 2010, Trends in pharmacological sciences.

[48]  Rafael Tabarés-Seisdedos,et al.  Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders , 2013, Nature Reviews Neuroscience.

[49]  Sudha Seshadri,et al.  Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study , 2012, BMJ : British Medical Journal.

[50]  D. Drachman Aging of the brain, entropy, and Alzheimer disease , 2006, Neurology.

[51]  G. Glenner,et al.  Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. , 1984, Biochemical and biophysical research communications.

[52]  A. Tsirigos,et al.  Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: Similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling" , 2010, Aging.

[53]  John Hardy,et al.  The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal , 2009, Journal of neurochemistry.

[54]  Energy-Efficient Action Potentials in Hippocampal , 2009 .

[55]  L. Demetrius,et al.  The inverse association of cancer and Alzheimer's: a bioenergetic mechanism , 2013, Journal of The Royal Society Interface.

[56]  T. Casoli,et al.  Ketogenic diets: An historical antiepileptic therapy with promising potentialities for the aging brain , 2010, Ageing Research Reviews.

[57]  David A. Bennett,et al.  REST and Stress Resistance in Aging and Alzheimer’s Disease , 2014, Nature.

[58]  M. Guzmán,et al.  Is there an astrocyte–neuron ketone body shuttle? , 2001, Trends in Endocrinology & Metabolism.

[59]  S. Rapoport,et al.  Downregulation of oxidative phosphorylation in Alzheimer disease: loss of cytochrome oxidase subunit mRNA in the hippocampus and entorhinal cortex , 1998, Brain Research.

[60]  L. Pellerin,et al.  Endothelial Cell-Derived Nitric Oxide Enhances Aerobic Glycolysis in Astrocytes via HIF-1α-Mediated Target Gene Activation , 2012, The Journal of Neuroscience.

[61]  Aitana Neves,et al.  Determinants of Brain Cell Metabolic Phenotypes and Energy Substrate Utilization Unraveled with a Modeling Approach , 2012, PLoS Comput. Biol..

[62]  G. S. Wilson,et al.  A Temporary Local Energy Pool Coupled to Neuronal Activity: Fluctuations of Extracellular Lactate Levels in Rat Brain Monitored with Rapid‐Response Enzyme‐Based Sensor , 1997, Journal of neurochemistry.

[63]  R. Tanzi,et al.  Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses , 2008, Nature Reviews Neuroscience.

[64]  Robert A. Harris,et al.  Phosphorylation status of pyruvate dehydrogenase distinguishes metabolic phenotypes of cultured rat brain astrocytes and neurons , 2010, Glia.

[65]  P. Magistretti,et al.  Ampakine™ CX546 bolsters energetic response of astrocytes: a novel target for cognitive‐enhancing drugs acting as α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptor modulators , 2005, Journal of neurochemistry.

[66]  J. Morrison,et al.  The aging brain: morphomolecular senescence of cortical circuits , 2004, Trends in Neurosciences.

[67]  K. Jellinger,et al.  Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature , 2012, Journal of neuropathology and experimental neurology.

[68]  I. Reynolds,et al.  Mitochondrial trafficking and morphology in healthy and injured neurons , 2006, Progress in Neurobiology.

[69]  S. Moncada,et al.  Glycolysis: a bioenergetic or a survival pathway? , 2010, Trends in biochemical sciences.

[70]  Panteleimon Giannakopoulos,et al.  Pathological substrates of cognitive decline in Alzheimer's disease. , 2009, Frontiers of neurology and neuroscience.

[71]  R. DeFronzo,et al.  Whole body overexpression of PGC-1alpha has opposite effects on hepatic and muscle insulin sensitivity. , 2009, American journal of physiology. Endocrinology and metabolism.

[72]  J Carter,et al.  Molecular Pathology of Alzheimer's Disease , 2013 .

[73]  L. Pellerin,et al.  Oxygen tension controls the expression of the monocarboxylate transporter MCT4 in cultured mouse cortical astrocytes via a hypoxia‐inducible factor‐1α‐mediated transcriptional regulation , 2014, Glia.